Fighting Chemotherapy Side Effects: Myelosuppression Treatment Market 2024

The new report published by The Business Research Company, titled Chemotherapy-Induced Myelosuppression Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the chemotherapy-induced myelosuppression treatment market size has grown steadily in recent years. It will grow from $7.65 billion in 2023 to $7.97 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The chemotherapy-induced myelosuppression treatment market size is expected to see steady growth in the next few years. It will grow to $9.60 billion in 2028 at a compound annual growth rate (CAGR) of 4.7%.

Download Free Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=16372&type=smp

Impact Of Rising Cancer Prevalence On The Chemotherapy-Induced Myelosuppression Treatment Market
The rising prevalence of cancer is expected to propel the growth of the chemotherapy-induced myelosuppression treatment market going forward. Cancer is the unregulated growth and spread of abnormal cells, often leading to the invasion of surrounding tissues and organs, disrupting their normal function, and potentially threatening the overall health and well-being of the individual. The prevalence of cancer is due to exposure to pollution, radiation, certain chemicals, and carcinogens. Chemotherapy-induced myelosuppression treatment is essential in cancer care for managing the hematological side effects caused by chemotherapy, which is a standard treatment modality for various types of cancer. For instance, in May 2024, according to the American Society of Clinical Oncology, a US-based professional organization, an estimated 20 million new cancer cases were found in 2022, and expected to reach 35 million new cases globally by 2050. Therefore, the rising prevalence of cancer is driving the chemotherapy-induced myelosuppression treatment market.

Innovative Developments In Myeloprotection Therapy For Chemotherapy-Induced Myelosuppression Treatment
Major companies operating in the chemotherapy-induced myelosuppression treatment market focus on developing innovative products, such as myeloprotection therapy, to enhance treatment efficacy and patient experience. Myeloprotection therapy refers to medical interventions to protect the bone marrow and hematopoietic stem cells from damage caused by specific treatments, particularly chemotherapy and radiation therapy. For instance, in February 2021, G1 Therapeutics Inc., a US-based biopharmaceutical company, launched COSELA (trilaciclib) for injection to lessen the frequency of myelosuppression caused by chemotherapy in adult patients, which was approved by the Food and Drug Administration (FDA), a US-based federal agency. This innovative approach alleviates common chemotherapy side effects like neutropenia, anemia, and thrombocytopenia, often leading to dose reductions or treatment delays. Cosela integrates smoothly into existing chemotherapy regimens across different cancer types, enhancing patient tolerance and supporting continuous therapy delivery, potentially improving overall treatment outcomes and quality of life.

The chemotherapy-induced myelosuppression treatment market covered in this report is segmented -

1) By Indication: Anemia, Neutropenia, Thrombocytopenia
2) By Drug Class: Growth Factors, Erythropoietin Stimulating Agents, Thrombopoietic Agents, Iron Supplements, Other Drug Classes
3) By Route Of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=16372&type=discount

Major companies operating in the chemotherapy-induced myelosuppression treatment market are Merck & Co. Inc., Bayer AG, Sanofi SA, Abbott Laboratories, Novartis AG, Glaxo Smith Kline plc, Amgen Inc., Viatris Inc., Biogen SA, Bausch Health Companies Inc., Cipla Inc., Hikma Pharmaceuticals PLC,Lupin Ltd, Seagen Inc, Mission Pharmacal Company, G1 Therapeutics Inc., Spectrum Pharmaceuticals Inc., Partner Therapeutics Inc., Myelo Therapeutics GmbH, Evive Biotech Inc.

Contents of the report:
1. Executive Summary
2. Chemotherapy-Induced Myelosuppression Treatment Market Report Structure
3. Chemotherapy-Induced Myelosuppression Treatment Market Trends And Strategies
4. Chemotherapy-Induced Myelosuppression Treatment Market - Macro Economic Scenario
5. Chemotherapy-Induced Myelosuppression Treatment Market Size And Growth
…..
27. Chemotherapy-Induced Myelosuppression Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-myelosuppression-treatment-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.